Market Pulse50Neutral

Globus Medical, Inc.Opportunity Rank #48(GMED) Intrinsic Value & DCF Analysis (2026)

Sector: Healthcare

Current Price

$87.21

Last updated: Mar 24, 2026

Price vs Intrinsic Value

$87.21
Price
$147.36
Intrinsic Value
Undervalued by 69%MOS: $117.89

Fundamental Score

73/100
Bullish

Weighted across 6 signals

Narrative Score

59/100
Improving

-1 vs previous

The intrinsic value of Globus Medical, Inc. (GMED) is estimated at $147.36 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $87.21, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 7.90% long-term growth rate and a 9.13% discount rate, reflecting expected future free cash flow and cost of capital.

The intrinsic value of Globus Medical, Inc. (GMED) is estimated at $147.36 per share based on a 10-year discounted cash flow (DCF) analysis. At the current price of $87.21, the stock appears undervalued relative to its projected cash flow fundamentals. This estimate assumes a 7.90% long-term growth rate and a 9.13% discount rate, reflecting expected future free cash flow and cost of capital.

Valuation Details

$147.36
▲ 68.97% upside
20% margin of safety: $117.89
Years: 10Growth Rate: 7.90%
Want to create your own valuation? Create a free account.

Capital Efficiency

Average Quarterly ROIC
2.9%
Cost of Capital (estimated)7%
Value StatusUnderperforming Capital

The company is earning below its required return. This may indicate inefficient use of capital or excess cash that isn't being reinvested.

Complete historical ROIC is available with
.

Fundamental Details

73/100
BullishWeighted across 6 signals
DCF Discount
69.0% discount to price
100
FCF Yield
7.9% trailing FCF yield
100
ROIC vs WACC
ROIC 2.9% vs WACC 7.0% (0.4x)
21
Net Debt / FCF
Net cash position
100
Buybacks
Share count growing
30
FCF CAGR (5Y)
28.7% 5Y FCF CAGR
100
Strengths: DCF Discount, FCF Yield. Concerns: ROIC vs WACC, Buybacks.

Narrative Details

59/100
Improving
-1 vs previousVs 6-Month Baseline:Average (52nd pct)Weighted across 6 recent drivers
Trend: Deteriorating downConfidence: 86%Updated: 1h ago
Sources: 37 (31 News · 6 Analyst)
Drivers(last 30 days)
18 news sentiment+0.5
10 regulatory scrutiny+0.3
Upgrade headlines+0.1
Macro headwinds+0.0
Earnings beat+0.0
Analyst upgrades+0.0

Investment Coach

Updated 19h ago
BUYConfidence: 65%
Thesis
Globus Medical, Inc. is undervalued with an estimated fair value 73% above its current price, supported by strong fundamentals including a healthy free cash flow yield of 7.9%. Despite trailing returns relative to its cost of capital, the company shows bullish indicators and improving narrative trends.
Key Risk
The key risk is the negative spread between ROIC and WACC, indicating returns are not currently covering the cost of capital.
Signals To Watch
  • Monitor whether valuation discount remains above 10%.
  • Track ROIC vs WACC spread for sustained improvement.
  • Follow narrative trend for meaningful shifts in the score direction.
Ask the Coach - Available with
Historical Growth Rates
Free Cash Flow- - -Trend CAGR: 7.90%5 Year CAGR: 22.74%

Free Cash Flow (in millions)

TTM20252024202320222021202020192018201720162015201420132012201120102009
$928$918$636$322$253$333$262$243$241$211$213$173$104$117$101$99$84$58

How Intrinziq Estimates Fair Value

Intrinziq estimates Globus Medical, Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Globus Medical, Inc.Healthcare

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.